GlassScriptPhysician profile
Opal Kamdar Gupta
NPI 1760724371
$5,765.34
in general payments reported to CMS, 2019-2025
34 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $317 · 2021: $400 · 2022: $660 · 2023: $333 · 2024: $1,921 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Consulting Fee: $902 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.67 |
| Consulting Fee | $901.85 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,583.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $691.95 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $515.02 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $369.98 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $260.92 | 2019-2025 | |
| Optinose US, INC. | $254.89 | 2019-2025 | |
| Blueprint Medicines Corporation | $226.39 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $191.59 | 2021-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $187.46 | 2019-2022 | |
| Amgen INC. | $181.02 | 2022-2025 | Tezspire, Actimmune |
| Kaleo, INC. | $128.24 | 2020-2022 | |
| Abbvie INC. | $127.53 | 2023-2025 | |
| Csl Behring | $112.50 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Galderma Laboratories, L.P. | $103.14 | 2025 | Nemluvio |
| Grifols USA, LLC | $93.52 | 2024-2025 | Xembify |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $76.90 | 2022-2025 | Opzelura |
| Alk-Abello, INC | $72.74 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $61.87 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $52.01 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.79 | 2019 | |
| Pfizer INC. | $49.15 | 2023-2024 | |
| Hospira, INC. | $48.52 | 2023-2025 | |
| Covis Pharma Gmbh | $44.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.02 | 2022 | |
| Jubilant Hollisterstier LLC | $31.66 | 2021 | |
| Octapharma USA, INC. | $29.50 | 2025 | Cutaquig |
| Lilly USA, LLC | $29.11 | 2025 | Ebglyss |
| Leo Pharma INC. | $28.93 | 2022 | |
| Organon LLC | $25.51 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $21.85 | 2024 | |
| Shire North American Group INC | $21.51 | 2019 | |
| Circassia INC. | $17.59 | 2019 | |
| Arcutis Biotherapeutics, INC. | $16.40 | 2025 | Zoryve |
| Biocryst US Sales Co., LLC | $16.00 | 2025 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Opal Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.